Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK Serevent Safety Label Change Coming Soon; Will Advair Be Affected?

Executive Summary

GlaxoSmithKline will meet with FDA to discuss the interim results from the company's halted Serevent safety study and determine whether the information should be added to product labeling

You may also be interested in...



Crestor, Serevent Safety Issues Push Vioxx Out Of Spotlight In Senate Hearing

FDA's focus following the Senate Finance Committee hearing on the Vioxx withdrawal is on defending the safety of five other drugs challenged by one of its safety reviewers

Crestor, Serevent Safety Issues Push Vioxx Out Of Spotlight In Senate Hearing

FDA's focus following the Senate Finance Committee hearing on the Vioxx withdrawal is on defending the safety of five other drugs challenged by one of its safety reviewers

GSK’s Advair, Serevent Add “Black Box” On Rare Asthma-Related Deaths

GlaxoSmithKline has revised labeling for Advair and Serevent to include "black box" warnings on an increased risk of asthma-related deaths in patients taking salmeterol

Related Content

UsernamePublicRestriction

Register

PS041157

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel